Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alipogene Tiparvovec in LPLD Patients
NCT02904772Phase 2Withdrawn
- Sponsor
- uniQure
- Start
- Oct 2016
- Primary completion
- Jun 2020
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 2
01
Overview
A Phase 2 trial of alipogene tiparvovec in lipoprotein lipase deficiency (LPLD), sponsored by uniQure. Planned start Oct 2016; status: withdrawn.
02
Drugs
alipogene tiparvovec
03
Conditions
lipoprotein lipase deficiency (LPLD)
Beyond the preview
Go deeper on NCT02904772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02904772.